Print Page  Close Window
Receive E-mail AlertsE-mail Alerts
Keyword Search
2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009
DateTitle 
07/30/15Alnylam to Webcast Conference Call Discussing Second Quarter 2015 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 30, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the second quarter ending June 30, 2015 on Thursday, August 6, 2015, after the U.S. financial markets close. Management will provide an update on the company, discuss second quarter 2015 results, and discuss expectations for the future via conference ... 
Printer Friendly Version
07/27/15Alnylam Initiates Phase 1/2 Clinical Trial for ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)
– Company Expects to Present Initial Clinical Results in Early 2016 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 27, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alp... 
Printer Friendly Version
07/20/15Alnylam Initiates Phase 3 Open Label Extension Study (“APOLLO-OLE”) with Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR Amyloidosis)
– Provides Opportunity for Patients who Participate in APOLLO Phase 3 Trial to Receive Patisiran on Ongoing Basis – – Consistent With Previous Guidance, Company Expects APOLLO, if Positive, to Enable New Drug Application (NDA) Filing in 2017 Timeframe – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 20, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated its Phase 3 o... 
Printer Friendly Version
07/16/15Alnylam to Reschedule First RNAi Roundtable Webcast
– ALN-CC5 for the Treatment of Complement-Mediated Diseases Rescheduled for Thursday, July 23, 9:00 – 10:00 a.m. ET – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 16, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that due to an unforeseen scheduling issue with its guest speaker, the first program in the company’s series of RNAi Roundtable webcasts has been rescheduled. “ALN-CC5 for ... 
Printer Friendly Version
07/06/15Alnylam to Host Second Annual Summer “RNAi Roundtable” Webcast Series
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 6, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast its annual summer series of online "RNAi Roundtables" this July, August, and September. The 2015 series of events will consist of presentations by a mix of Alnylam scientists, clinical collaborators, and patient advocates, who will review recent progress in many of th... 
Printer Friendly Version
06/23/15Alnylam Reports New Positive Clinical Data for ALN-AT3, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders
– New Interim Data from Ongoing Phase 1 Study in Hemophilia Subjects Demonstrate an up to 86% AT Knockdown and a Re-Balancing of Hemostasis with Normalization of Thrombin Generation up to a Mean Increase of 350% and Marked Improvements in Whole Blood Clotting – – In Exploratory Post Hoc Analysis, Reduced Bleeding Events Associated with AT Knockdown, with a Maximum Bleed-Free Interval of 114 Days – – ALN-AT3 Administration Remains G... 
Printer Friendly Version
06/12/15Alnylam Reports Positive Initial Clinical Results for ALN-CC5, an Investigational RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases
– In Ongoing Phase 1/2 Study, Single Subcutaneous Doses of ALN-CC5 Achieve Potent, Statistically Significant, and Highly Durable C5 Knockdown of up to 96% – – After Single Dose, ALN-CC5 Also Achieves up to 92% Inhibition of Serum Complement Activity, Including up to 61% Inhibition of Serum Hemolytic Activity, and was Generally Well Tolerated – – Dose Escalation Continues in Multi-Dose Cohorts, with Additional Data Expected to be Pr... 
Printer Friendly Version
06/10/15Alnylam Files Trade Secret Misappropriation Suit Against Dicerna Pharmaceuticals
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 10, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has filed a trade secret misappropriation lawsuit against Dicerna Pharmaceuticals, Inc. in the Superior Court of Middlesex County, Massachusetts. By this lawsuit, Alnylam seeks to stop misappropriation by Dicerna of the company’s confidential, proprietary, and trade secret information ... 
Printer Friendly Version
06/08/15Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 8, 2015-- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading RNAi therapeutics company, today announced the appointment of David-Alexandre “DA” Gros, M.D. to the position of Senior Vice President, Chief Business Officer. Dr. Gros joins Alnylam with extensive experience in the pharmaceutical industry and in healthcare investment banking and consulting. At Alnylam, he will be responsible for the com... 
Printer Friendly Version
06/05/15Alnylam to Present New Data at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress with ALN-AT3, an Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)
– Interim Phase 1 Results to be Highlighted in an Oral Presentation on ALN-AT3 as a Potential Disease Modifying Approach for People with Hemophilia A or B – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 5, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it will present new interim Phase 1 clinical data and additional pre-clinical study results on ALN-AT3 – an investigational RNAi t... 
Printer Friendly Version
05/28/15Alnylam to Webcast Presentations at Upcoming June Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 28, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the following conferences in June: Jefferies 2015 Healthcare Conference on Thursday, June 4, 2015 at 8:30 a.m. ET in New York City Goldman Sachs 36th Annual Healthcare Conference on Wednesday, June 10, 201... 
Printer Friendly Version
05/26/15Alnylam Initiates Phase 1 Clinical Trial for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias, Including Acute Intermittent Porphyria (AIP)
– Company Expects to Present Initial Clinical Results in Early 2016 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 26, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 clinical trial with ALN-AS1, a subcutaneously administered investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias, including... 
Printer Friendly Version
05/20/15Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for Revusiran, an Investigational RNAi Therapeutic for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 20, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to revusiran, an investigational RNAi therapeutic, for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis). Revusiran is currently in Phase 3 development for the treatment of Familia... 
Printer Friendly Version
05/17/15Alnylam Files Clinical Trial Application (CTA) for ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)
– Company Guides that it Plans to Initiate Phase 1/2 Trial in Late 2015 and Report Initial Clinical Results in Early 2016 – – New Pre-Clinical Data with ALN-AAT Presented at Digestive Disease Week (DDW) Meeting, Showing Robust Knockdown of Serum AAT of Up to 93% with Monthly Subcutaneous Dosing in Non-Human Primates and a Wide Therapeutic Index – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2015-- Alnylam Pharmaceuticals, Inc. (NA... 
Printer Friendly Version
05/07/15Alnylam Pharmaceuticals Reports First Quarter 2015 Financial Results and Highlights Recent Period Progress
– Launched “Alnylam 2020” Guidance for Advancement and Commercialization of RNAi Therapeutics – – Advanced Multiple Clinical Programs and Presented Evidence for Potential Disease-Modifying Activity for Patisiran in Familial Amyloidotic Polyneuropathy (FAP) and ALN-AT3 in Hemophilia – – Plans to Present New Clinical Data for ALN-AT3 and Initial Clinical Data for ALN-CC5 in Oral Presentations at Medical Meetings in June – – M... 
Printer Friendly Version
04/30/15Alnylam to Webcast Conference Call Discussing First Quarter 2015 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 30, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the first quarter ending March 31, 2015 on Thursday, May 7, 2015, after the U.S. financial markets close. Management will provide an update on the company, discuss first quarter 2015 results, and discuss expectations for the future via conference ... 
Printer Friendly Version
04/29/15Alnylam to Webcast Presentations at Upcoming May Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 29, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the following conferences in May: Deutsche Bank 40th Annual Health Care Conference on Wednesday, May 6, 2015 at 4:10 p.m. ET at the InterContinental Hotel in Boston Bank of America Merrill Lynch 2015 Hea... 
Printer Friendly Version
04/21/15Alnylam Reports 12-Month Clinical Data from Phase 2 Open Label Extension (OLE) Study of Patisiran, an Investigational RNAi Therapeutic for Patients with Familial Amyloidotic Polyneuropathy (FAP)
– A Mean 2.5 Point Decrease in mNIS+7 Endpoint Compares Favorably to 13 to 18 Point Increase Estimated from Analysis of Historical Data Sets, and is Consistent with Therapeutic Hypothesis that Transthyretin (TTR) Knockdown has the Potential to Halt Neuropathy Progression – – Based on Promising Results, Company Now Plans to Report 18-Month OLE Clinical Data in Late 2015 – – Company to Host Conference Call Today at 9:00 a.m. ET to Di... 
Printer Friendly Version
04/13/15Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3, an Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)
– New Paper Documents Safety, Efficacy, and Durability of Subcutaneous Doses of ALN-AT3 in Rodent and Non-Human Primate (NHP) Models of Hemophilia – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 13, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication in Nature Medicine of pre-clinical results with ALN-AT3, an investigational RNAi therapeutic targeting antithrombin (AT) for ... 
Printer Friendly Version
04/08/15Alnylam to Webcast Presentation at 14th Annual Needham Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 8, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 12:10 p.m. ET at the Westin Grand Central Hotel in New York City. A live audio webcast of the presentation will be available on the Investors section of the c... 
Printer Friendly Version
03/15/15Alnylam Presents Results from Natural History Study of Patients with Familial Amyloidotic Cardiomyopathy (FAC) and Presents Complete Results from Phase 2 Clinical Trial for Revusiran, an Investigational RNAi Therapeutic for the Treatment of FAC
Natural History Study Results Describe an Average Decline of Approximately 140 Meters in 6-Minute Walk Distance (6-MWD) over 18 Months, Further Validating Co-Primary Endpoint in ENDEAVOUR Phase 3 Study of Revusiran in FAC CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 15, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today results from a retrospective natural history study evaluating disease... 
Printer Friendly Version
03/13/15Alnylam to Webcast Presentation at 22nd Annual Future Leaders in the Biotech Industry Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 13, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 22nd Annual Future Leaders in the Biotech Industry Conference on Friday, March 20, 2015 at 10:00 a.m. ET at the Millennium Broadway Hotel in New York City. A live audio webcast of the presentation will be available on the Investors... 
Printer Friendly Version
03/05/15Alnylam to Webcast Presentation at Barclays Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Thursday, March 12, 2015 at 10:15 a.m. ET at the Loews Miami Beach Hotel in Miami, Florida. A live audio webcast of the presentation will be available on the Investors section of the company’s websi... 
Printer Friendly Version
02/25/15Alnylam to Webcast Presentation at Cowen & Company 35th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Cowen and Company 35th Annual Health Care Conference on Wednesday, March 4, 2015 at 10:00 a.m. ET at the Boston Marriott Copley Place Hotel in Boston. A live audio webcast of the presentation will be available on the Investors sect... 
Printer Friendly Version
02/18/15Alnylam to Webcast Presentation at 2015 RBC Capital Markets’ Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 18, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 2015 RBC Capital Markets’ Global Healthcare Conference on Wednesday, February 25, 2015 at 9:30 a.m. ET at the New York Palace Hotel in New York City. A live audio webcast of the presentation will be available on the Investors secti... 
Printer Friendly Version
02/12/15Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Recent Period Progress
– Introduced Pipeline Growth Strategy for RNAi Therapeutics in Three Strategic Therapeutic Areas, or “STArs,” and Launched “Alnylam 2020” Guidance for Advancement and Commercialization of RNAi Therapeutics – – Presented Positive Data from Multiple Clinical Programs, Including Initial Evidence of Potential Disease Modifying Effects with Patisiran and ALN-AT3 – – Advanced Revusiran into ENDEAVOUR Phase 3 Trial and Added Three New Pro... 
Printer Friendly Version
02/05/15Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 5, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the fourth quarter and year ending December 31, 2014 on Thursday, February 12, 2015, after the U.S. financial markets close. Management will provide an update on the company, discuss fourth quarter and year-end 2014 results, and discuss expectations fo... 
Printer Friendly Version
02/03/15Alnylam to Webcast Presentation at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 3, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015 at 11:00 a.m. ET at the Waldorf Astoria in New York City. In addition, Alnylam management will present a company overview at the 2015 Leerink Global Healthca... 
Printer Friendly Version
02/02/15Alnylam Initiates Phase 1/2 Clinical Trial for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases
Company Expects to Present Initial Clinical Results in Mid-2015 with Additional Data in Late 2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that it has initiated a Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-m... 
Printer Friendly Version
01/20/15Alnylam Pharmaceuticals Announces Proposed Public Offering of $450 Million of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 20, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $450 million. All of the shares in the offering are to be sold by Alnylam. J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are acting as joint book-runn... 
Printer Friendly Version
01/20/15Alnylam Pharmaceuticals Prices Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 20, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced the pricing of an underwritten registered public offering of 4,736,842 shares of its common stock at a public offering price of $95 per share. All of the shares in the offering are to be sold by Alnylam. The offering is expected to close on or about January 26, 2015, subject to the satisfaction of customary ... 
Printer Friendly Version
01/11/15Alnylam Reports Initial Evidence for Potential Correction of the Hemophilia Phenotype in Phase 1 Study of ALN-AT3, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia
– In New Data from Hemophilia Subjects, ALN-AT3 Achieves Antithrombin Knockdown of up to 70%, Increases Thrombin Generation by up to 334%, and Markedly Improves Whole Blood Clotting – – ALN-AT3 Administration Remains Generally Well Tolerated – – Company to Webcast Conference Call at 8:30 a.m. ET (5:30 a.m. PT) Tomorrow, January 12, to Discuss Data – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 11, 2015-- Alnylam Pharm... 
Printer Friendly Version
01/09/15Alnylam and Isis Form New Agreement, Extending Decade-Long Partnership for Leadership in RNA Therapeutics
New Agreement Includes Cross-License on Four Disease Targets, Providing Each Company Exclusive RNA Therapeutic License Rights for Two Programs CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2015-- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), leaders in RNA-targeted therapeutics, announced today they have formed a new agreement, extending their existing strategic partnership – formed originally in ... 
Printer Friendly Version
01/08/15Alnylam Launches “Alnylam 2020” Guidance for Advancement and Commercialization of RNAi Therapeutics
– By End of 2020, Company Expects to Achieve Profile with 3 Marketed Products, 10 RNAi Therapeutic Clinical Programs - Including 4 in Late Stages - Across 3 Strategic Therapeutic Areas (STArs) – – Provides Goals and Guidance for 2015, Exceeding its “Alnylam 5x15” Guidance Established in 2011 and Further Updated in 2014 – – Increases Guidance to End 2014 with Approximately $880 Million in Cash – CAMBRIDGE, Mass.--(BUSINESS WIRE)... 
Printer Friendly Version
01/05/15Alnylam Files Clinical Trial Application to Initiate a Phase 1 Study for ALN-AS1, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias
Company Expects to Initiate Phase 1 Study in Mid-2015 with Initial Clinical Results in Early 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 5, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Swedish Medical Products Agency (MPA) to initiate a Phase 1 clinical trial with ALN-AS1, a subcutaneously administered investigation... 
Printer Friendly Version
01/05/15Alnylam to Webcast Presentation at 33rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 5, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 10:00 a.m. PT (1:00 p.m. ET) at the Westin St. Francis Hotel in San Francisco, Calif. This presentation will include a review of the company’s goals and guidance. ... 
Printer Friendly Version

This part of our website contains archived information which should not be considered current and may no longer be accurate.